188 related articles for article (PubMed ID: 37214268)
1. Claudin18.2-targeted cancer theranostics.
Zhang D; Huang G; Liu J; Wei W
Am J Nucl Med Mol Imaging; 2023; 13(2):64-69. PubMed ID: 37214268
[TBL] [Abstract][Full Text] [Related]
2. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
3. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
4. Development and comparison of
Wei W; Zhang D; Zhang Y; Li L; Jin Y; An S; Lv C; Zhao H; Wang C; Huang Y; Dong J; Huang G; Liu J
Mol Ther Oncolytics; 2022 Dec; 27():305-314. PubMed ID: 36570796
[TBL] [Abstract][Full Text] [Related]
5. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
6. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
Lee HJ; Hwang SJ; Jeong EH; Chang MH
J Microbiol; 2024 May; ():. PubMed ID: 38700775
[TBL] [Abstract][Full Text] [Related]
7. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.
Zhang J; Dong R; Shen L
Chin J Cancer Res; 2020 Apr; 32(2):263-270. PubMed ID: 32410803
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
[TBL] [Abstract][Full Text] [Related]
10. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC).
Xu B; Liu F; Liu Q; Shi T; Wang Z; Wu N; Xu X; Li L; Fan X; Yu L; Liu B; Wei J
J Gastrointest Oncol; 2020 Dec; 11(6):1431-1439. PubMed ID: 33457012
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma.
Liu J; Yang H; Yin D; Jia Y; Li S; Liu Y
Pathol Res Pract; 2022 Oct; 238():154068. PubMed ID: 36007395
[TBL] [Abstract][Full Text] [Related]
12. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors.
Chen Y; Hou X; Li D; Ding J; Liu J; Wang Z; Teng F; Li H; Zhang F; Gu Y; Yu S; Qian X; Yang Z; Zhu H
J Pharm Anal; 2023 Apr; 13(4):367-375. PubMed ID: 37181294
[TBL] [Abstract][Full Text] [Related]
13. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
15. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
16. Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.
Xu Q; Jia C; Ou Y; Zeng C; Jia Y
Front Oncol; 2024; 14():1371421. PubMed ID: 38511141
[TBL] [Abstract][Full Text] [Related]
17. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications.
Chen J; Xu Z; Hu C; Zhang S; Zi M; Yuan L; Cheng X
Front Oncol; 2023; 13():1132319. PubMed ID: 36969060
[TBL] [Abstract][Full Text] [Related]
18. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
Sahin U; Koslowski M; Dhaene K; Usener D; Brandenburg G; Seitz G; Huber C; Türeci O
Clin Cancer Res; 2008 Dec; 14(23):7624-34. PubMed ID: 19047087
[TBL] [Abstract][Full Text] [Related]
19. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.
Zeng Y; Lockhart AC; Jin RU
Expert Opin Drug Discov; 2024 Jun; ():1-14. PubMed ID: 38919123
[TBL] [Abstract][Full Text] [Related]
20. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]